CON group | (n = 21) | PRO group | (n = 19) | P-values | |||
---|---|---|---|---|---|---|---|
0 weeks | 5 weeks | 0 weeks | 5 weeks | Training | Treatment | Interaction | |
Age (yr) | 22.5 ± 2.3 | 21.5 ± 1.6 | |||||
Body mass (kg) | 77.2 ± 7.2 | 76.3 ± 5.4 | |||||
Height (m) | 1.85 ± 0.1 | 1.85 ± 0.1 | |||||
BMI (kg/m-2) | 22.4 ± 1.3 | 22.3 ± 1.5 | |||||
Lean mass (kg) | 61.0 ± 4.2 | 61.1 ± 4.1 | 60.1 ± 4.8 | 61.6 ± 5.3 | = 0.0001 | = 0.9 | = 0.000 |
Fat mass (kg) | 12.8 ± 4.5 | 12.7 ± 4.6 | 12.8 ± 2.9 | 12.2 ± 3.1 | = 0.02 | = 0.8 | = 0.089 |
VO2max (L·min-1) | 3.9 ± 0.3 | 4.1 ± 0.3 | 3.8 ± 0.4 | 4.2 ± 0.5 | = < 0.0001 | = 0.7 | = 0.004 |
VO2max (mL·kg-1·min-1) | 50.8 ± 3.9 | 53.0 ± 4.9 | 49.9 ± 3.4 | 54.9 ± 4.8 | = < 0.0001 | = 0.7 | = 0.016 |
Citrate synthase (μmol·g − 1·min − 1) | 21.8 ± 5.4 | 28.7 ± 4.4 | 23.4 ± 6.2 | 31.9 ± 5.2 | = < 0.0001 | = 0.1 | = 0.206 |
Time-trial performance (seconds) | 982.3 ± 86.1 | 871.1 ± 45.8 | 957.8 ± 106.5 | 839.1 ± 53.4 | = < 0.0001 | = 0.1 | = 0.796 |